Literature DB >> 32726723

Acute onset olfactory/taste disorders are associated with a high viral burden in mild or asymptomatic SARS-CoV-2 infections.

Kensuke Nakagawara1, Katsunori Masaki2, Yoshifumi Uwamino3, Hiroki Kabata1, Sho Uchida4, Shunsuke Uno4, Takanori Asakura1, Takeru Funakoshi5, Sho Kanzaki6, Makoto Ishii1, Naoki Hasegawa4, Koichi Fukunaga1.   

Abstract

This study investigated, using cycle threshold (Ct) qPCR values, the association between symptoms and viral clearance in 57 patients with asymptomatic/mild SARS-CoV-2 infection. Patients with olfactory/taste disorders (OTDs) exhibited lower qPCR Ct values and longer time to negative qPCR than those without OTDs, suggesting an association between OTDs and high viral burden.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  COVID-19; Cycle threshold (Ct) values; Olfactory/taste disorders (OTDs); Real-time polymerase chain reaction (qPCR); SARS-CoV-2

Mesh:

Year:  2020        PMID: 32726723      PMCID: PMC7382961          DOI: 10.1016/j.ijid.2020.07.034

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread globally. In Tokyo, Japan, the total number of confirmed cases has increased, particularly from March to April 2020. Real-time polymerase chain reaction (qPCR) using clinical specimens such as nasopharyngeal swabs or sputum is the standard of reference for diagnosis, and recent studies have shown an association between qPCR cycle threshold (Ct) values and disease severity (Liu et al., 2020, Yu et al., 2020). Specifically, Ct values from qPCR tests conducted on nasopharyngeal or sputum specimens of patients on admission were negatively associated with disease severity and progression to severe illness, and mild patients showed an early viral clearance using Ct values (Liu et al., 2020, Yu et al., 2020). However, little is known about the association between symptoms and viral clearance. This study investigated this association in mild/asymptomatic cases using qPCR Ct values of nasopharyngeal swab samples.

Method

Fifty-seven patients with asymptomatic/mild SARS-CoV-2 infection (without pneumonia or any organ failure) who were admitted to Keio University Hospital for isolation and/or treatment from March 28 to April 23, 2020 were included in this study. All patients had no symptoms of dyspnea and no findings of pneumonia on chest x-ray on admission. They were diagnosed with SARS-CoV-2 infection using qPCR conducted upon admission and did not receive any antiviral treatments. Pre-admission symptoms were collected at admission. After admission, patients were prospectively checked daily by physicians for symptoms such as fever, sore throat, nasal drip/congestion, cough/sputum, olfactory and taste disorders (OTDs), headache, fatigue, joint pain, and diarrhea. qPCR was performed on all nasopharyngeal swab samples using the SARS-CoV-2 CDC assay protocol and Ct values were reported for two genetic markers: the N1 and N2 viral nucleocapsid protein gene regions (Centers for Disease Control and Prevention, 2020). A value of ≤45 cycles indicated a positive result for SARS-CoV-2. qPCR testing was repeated every 3–7 days until the results were negative. This study retrospectively assessed the association between symptoms and Ct values or the period to negative qPCR.

Results

The clinical characteristics and symptoms of the patients are shown in Appendix A. The mean age was 35.4 years and 25 patients (43.9%) were males. Thirty-four patients (59.6%) had comorbidities (all under control). The most common disease was neoplasia (12.3%), followed by asthma (8.8%) and psychiatric disorders (7.0%). Twenty-eight patients (49.1%) were asymptomatic, with common symptoms on clinical courses being fever (15; 26.3%), sore throat (11; 19.3%), acute onset OTDs (10; 17.5%), headache (7; 12.3%), cough/sputum (8; 14.0%), and nasal drip/congestion (4; 7.0%). Figure 1 shows the prevalence of each symptom over time. Fever, sore throat and nasal drip congestion were relatively early and prolonged for about 1 week. The median duration of fever was 3 days (IQR 2.0–4.75 days, minimum: 1 day, maximum: 10 days). Cough and headache may be prolonged from early to late onset. The median duration of cough and sputum was 10 days (IQR 6.0–16.0 days, minimum: 2 days, maximum: 30 days).
Figure 1

Prevalence of symptoms during the time course. Days 0 indicates the date of the first positive RT-PCR result.

Prevalence of symptoms during the time course. Days 0 indicates the date of the first positive RT-PCR result. OTDs occurred in the later phase of disease compared with fever and sore throat. The median duration of OTDs was 9 days (IQR 4.5–16.3 days, minimum: 2 days, maximum: >30 days). Patients required a median of two rounds of qPCR testing (range: 2–9 times) to achieve a negative result. The median time to first negative qPCR was 8.5 days (range: 4–24 days). Ct values at admission were significantly associated with the time to negative qPCR (Appendix B). Furthermore, Ct values upon admission and the time to negative qPCR were significantly lower in patients with OTDs and fever (Figure 2) but not the other symptoms (Appendix C).
Figure 2

Comparisons of Ct values of the N1/N2 gene in SARS-CoV-2-infected patients with/without fever or acute onset olfactory/taste disorders.

Comparisons of Ct values of the N1/N2 gene in SARS-CoV-2-infected patients with/without fever or acute onset olfactory/taste disorders. These results show that patients with asymptomatic or mild SARS-CoV-2 infection with a higher viral load required a longer time to exhibit negative qPCR results, suggesting that Ct values reflect viral load in principle (Arons et al., 2020). Moreover, the results demonstrated that fever and OTDs were significantly associated with a higher viral burden and longer time to negative qPCR. Compared with fever, data on OTDs are less available, unless intentionally assessed, even though OTDs are a common symptom in SARS-CoV-2 infection (Sedaghat et al., 2020, Beltrán-Corbellini et al., 2020, Giacomelli et al., 2020). Recent studies have revealed that ACE2 (SARS-CoV-2 entry receptor) and TMPRSS2 (viral entry-associated protease) mRNAs are highly expressed in nasal epithelial cells, which suggests that the nasal cavity may be an important site for viral replication (Sungnak et al., 2020, Hou et al., 2020). Consistent with data from basic studies, patients with OTDs had a higher viral burden and required a longer time for viral clearance. The assessment of OTDs, including the avoidance of mechanical contact with the nasal cavity in OTD patients, may be important in preventing SARS-CoV-2 transmission. This study had some limitations. First, it did not include severe patients because all study participants recovered well. Second, the diagnosis of OTDs was self-reported and no objective or physiological tests were performed. However, the symptoms that were prospectively collected reflected viral burden, even though the questionnaire was predetermined. In conclusion, higher qPCR Ct values at diagnosis were associated with longer time to negative qPCR results, fever and OTDs. Physicians should carefully assess OTDs in patients with SARS-CoV-2 infection during disease, even in mild cases, as they may be associated with a high viral burden.

Conflict of interest

None.

Funding source

None.

Ethical approval

This study protocol was approved by the hospital’s Ethics Committee.
Study population

No. of patients57
Age, mean ± SD35.4 ± 13.6
Sex, male, no. (%)25 (43.9%)
Pregnant2 (3.5%)
Comorbiditiesno. (%)

No comorbidity23 (30.4)
Malignant tumor/Neoplasm7 (12.3)
Asthma5 (8.8)
Psychiatric disorder4 (7.0)
Gynecologic disease3 (5.3)
Allergic rhinitis2 (3.5)
Atopic dermatitis2 (3.5)
Gastrointestinal disease2 (3.5)
Cardiovascular disease1 (1.8)
Traumatic subarachnoid hemorrhage1 (1.8)
Diabetes1 (1.8)
Dyslipidemia1 (1.8)
Herpes labialis1 (1.8)
Migraine1 (1.8)
Symptomsno. (%)

Fever (>37.4 °C)15 (26.3)
Sore throat11 (19.3)
Acute onset olfactory/taste disorders10 (17.5)
Cough/sputum8 (14.0)
Headache7 (12.3)
Fatigue4 (7.0)
Nasal drip/congestion4 (7.0)
Joint pain1 (1.8)
Diarrhea1 (1.8)
  8 in total

1.  Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.

Authors:  Mackenzie E Hannum; Riley J Koch; Vicente A Ramirez; Sarah S Marks; Aurora K Toskala; Riley D Herriman; Cailu Lin; Paule V Joseph; Danielle R Reed
Journal:  Chem Senses       Date:  2022-01-01       Impact factor: 3.160

2.  Seroprevalence of anti-SARS-CoV-2 antibodies in Japanese COVID-19 patients.

Authors:  Makoto Hiki; Yoko Tabe; Tomohiko Ai; Yuya Matsue; Norihiro Harada; Kiichi Sugimoto; Yasushi Matsushita; Masakazu Matsushita; Mitsuru Wakita; Shigeki Misawa; Mayumi Idei; Takashi Miida; Naoto Tamura; Kazuhisa Takahashi; Toshio Naito
Journal:  PLoS One       Date:  2021-04-06       Impact factor: 3.240

3.  Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis.

Authors:  Endang Mutiawati; Syahrul Syahrul; Marhami Fahriani; Jonny Karunia Fajar; Sukamto S Mamada; Helnida Anggun Maliga; Nur Samsu; Muhammad Ilmawan; Yeni Purnamasari; Annisa Ayu Asmiragani; Ichsan Ichsan; Talha Bin Emran; Ali A Rabaan; Sri Masyeni; Firzan Nainu; Harapan Harapan
Journal:  F1000Res       Date:  2020-11-12

4.  Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.

Authors:  Masaru Takeshita; Naoshi Nishina; Saya Moriyama; Yoshimasa Takahashi; Yoshifumi Uwamino; Mika Nagata; Wataru Aoki; Katsunori Masaki; Makoto Ishii; Hideyuki Saya; Yasushi Kondo; Yuko Kaneko; Katsuya Suzuki; Koichi Fukunaga; Tsutomu Takeuchi
Journal:  Virology       Date:  2021-01-06       Impact factor: 3.513

5.  Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19.

Authors:  Andrea Ciofalo; Carlo Cavaliere; Simonetta Masieri; Alessandra Di Chicco; Irene Fatuzzo; Federica Lo Re; Silvia Baroncelli; Elona Begvarfaj; Andrea Adduci; Ivano Mezzaroma; Claudio Maria Mastroianni; Marco de Vincentiis; Antonio Greco; Loris Zamai; Marco Artico
Journal:  Cells       Date:  2022-02-24       Impact factor: 6.600

6.  The Prevalence and Implications of Olfactory/Gustatory Dysfunctions among Adult COVID-19 Patients: A Retrospective Cohort Multiethnic Populations Study.

Authors:  Wael Hafez; Mahmoud Abdelshakor; Muneir Gador; Ikram Abdelli; Shougyat Ahmed
Journal:  Trop Med Infect Dis       Date:  2022-06-23

Review 7.  Chemosensory Dysfunction in COVID-19: Integration of Genetic and Epidemiological Data Points to D614G Spike Protein Variant as a Contributing Factor.

Authors:  Rafal Butowt; Katarzyna Bilinska; Christopher S Von Bartheld
Journal:  ACS Chem Neurosci       Date:  2020-09-30       Impact factor: 4.418

8.  Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction.

Authors:  Sven Saussez; Shilpee Sharma; Anaïs Thiriard; Véronique Olislagers; Inès Vu Duc; Serge-D Le Bon; Mohamad Khalife; Stephane Hans; Giacomo De Riu; Claire Hopkins; Jerome R Lechien; Luigi A Vaira; Arnaud Marchant
Journal:  Eur J Neurol       Date:  2021-07-09       Impact factor: 6.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.